Welcome

Welcome to the website for Transregional Collaborative Research Center (CRC) SFB TR-128 Initiating/effector versus regulatory mechanisms in Multiple Sclerosis – progress towards tackling the disease. On this site you will find general information regarding the CRC as well as more specific information about its individual research projects.

Multiple Sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system (CNS) in the western world and it leads to devastating disability in young adults, with only limited treatment options currently available. The socioeconomic burden of this disease is tremendous, since healthcare costs are very high and it affects decisions young patients must make for the rest of their lives. Findings in patients are a complex composite of inflammation (with demyelination, remyelination, axonal/neuronal damage) typically in subcortical, but also cortical, disseminated lesions as well as neurodegeneration. Remissions of clinical relapses point to repair capacities of the CNS, which exhibits strong interindividual and course dependent differences.

Heinz Wiendl
Spokesperson

Frauke Zipp
Co-Spokesperson

News

Thu, 29/08/2019
Symposium: Multiple Sclerosis: balancing effector and regenerative pathways
The International Symposium of the Collaborative Research Centre 128 “Multiple Sclerosis” will take place from 08:30 on Monday 16th until 14:00 on Tuesday 17th September, 2019 at the University Medical Center in Mainz and will end with a general assembly for SFB members. A full program for the meeting can be found here....more
Mon, 03/06/2019
Publication: Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Muenster. For the first time scientists from the University of Münster could show that multiple sclerosis (MS) alters the energy metabolism of T cells during acute phases of disease exacerbation. Therapeutic interventions targeting the metabolism of activated T cells display new potential avenues for treatment of patients with MS affecting around 250,000 people in Germany. The […]...more
Mon, 29/04/2019
Publication: Calcium influx through plasma-membrane nanoruptures drives axon degeneration in a model of multiple sclerosis.
Munich.  Here SFB researchers from Munich use in vivo calcium imaging in a multiple sclerosis model to show that cytoplasmic calcium levels determine the choice between axon loss and survival. Calcium can enter the axon through nanoscale ruptures of the axonal plasma membrane that are induced in inflammatory lesions. Neuron doi: 10.1016/ j.neuron.2018.12.023...more